近日，辉瑞宣布终止针对呼吸道合胞病毒（RSV）治疗药物sisunatovir的开发。根据10月7日ClinicalTrials.gov网站的更新，辉瑞已经停止了两项关于sisunatovir治疗RSV感染的临床研究。

GSK plc (LSE/NYSE: GSK) has released new data from the AReSVi-006 Phase III trial, demonstrating the efficacy and safety of ...

AUSTIN (KXAN) — In 2023, the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP) ...

In most cases, adequate hydration and over-the-counter pain relievers can help manage your symptoms during the week or two it ...

GSK said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in ...

The Eastern Ontario Health Unit is advising a new treatment is now available in the region to help protect infants from the most-severe effects of respiratory syncytial virus (RSV).

The CDC recommends that all individuals aged 75 and older, as well as adults aged 60 and older who are at risk for severe RSV ...

辉瑞(PFE.US)美股盘前跌超2.6%，报29.4美元。消息面上，辉瑞已终止两项Sisunatovir治疗呼吸道合胞病毒(RSV)感染的临床研究。Sisunatovir是一种口服RSV融合蛋白抑制剂，旨在阻止RSV病毒与宿主细胞的融合。辉瑞发言人表 ...

Researchers from Brigham and Women’s Hospital published new research in Science Translational Medicine showing that natural ...

周四，H.C. Wainwright重申了对Enanta Pharmaceuticals (NASDAQ:ENTA)的买入评级，目标价为$27.00。这一评级的确认是在Enanta宣布其针对呼吸道合胞病毒(RSV)治疗候选药物EDP-323的2a期人体挑战研究取得令人鼓舞的顶线结果之后。 这项于2022年9月26日开始的研究，测试了EDP-323对健康成年人感染RSV后的抗病毒效果。主要疗效终点是 ...

葛兰素史克的数据显示，疫苗的效力逐渐减弱，从第二个季度的56.1%降至第三个季度的48%。由于对严重RSV疾病的定义不同，很难直接比较各种疫苗之间的疗效。尽管如此，Moderna疫苗的疗效被认为比其竞争对手下降得更快。

制药巨头GSK和辉瑞制药公司的RSV疫苗销量在美国出现显著下降。这一下降趋势源于监管机构决定缩小疫苗接种的年龄范围，并将其归类为终身一次性接种，导致数百万人今年无法再次接种该疫苗。 独立药剂师报告称，与去年秋季相比，需求下降了多达三分之二，医疗保健公司IQVIA的数据也支持这一观察结果。 这些疫苗是两家公司战略的关键部分，旨在在其畅销药品面临仿制药竞争之前建立新的产品线，但现在销售正在下滑。特别是 ...